Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study

Transfemoral transcatheter aortic valve replacement for pure native aortic regurgitation: one-year outcomes of a single-center study

Abstract Background Evidence about safety and efficacy of transcatheter aortic valve replacement (TAVR) with the Venus A-Valve system (Venus Medtech, Hangzhou, China) remains limited for patients with pure native aortic regurgitation (PNAR). Objectives The single-center study sought to report the on...

Full description

Bibliographic Details
Main Authors: Hua-Jie Zheng, Yong-Bo Cheng, Chao-Jun Yan, De-Qing Lin, San-Jiu Yu, Jun Li, Ping He, Wei Cheng
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cardiovascular Disorders
Subjects:
Transcatheter aortic valve replacement
Pure native aortic regurgitation
Venus A-Valve
Clinical outcomes
Online Access:https://doi.org/10.1186/s12872-023-03329-1

Internet

https://doi.org/10.1186/s12872-023-03329-1

Similar Items